Synthetic Biology Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), National University of Singapore, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; NUS Graduate School of Integrative Sciences and Engineering (NGS), National University of Singapore, Singapore.
Synthetic Biology Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), National University of Singapore, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Trends Cancer. 2021 May;7(5):447-464. doi: 10.1016/j.trecan.2020.11.004. Epub 2020 Dec 8.
Recent advancements in cancer biology, microbiology, and bioengineering have spurred the development of engineered live biotherapeutics for targeted cancer therapy. In particular, natural tumor-targeting and probiotic bacteria have been engineered for controlled and sustained delivery of anticancer agents into the tumor microenvironment (TME). Here, we review the latest advancements in the development of engineered bacteria for cancer therapy and additional engineering strategies to potentiate the delivery of therapeutic payloads. We also explore the use of combination therapies comprising both engineered bacteria and conventional anticancer therapies for addressing intratumor heterogeneity. Finally, we discuss prospects for the development and clinical translation of engineered bacteria for cancer prevention and treatment.
近年来，癌症生物学、微生物学和生物工程的进展推动了靶向癌症治疗的工程化活体生物治疗药物的发展。特别是，天然的肿瘤靶向和益生菌细菌已被工程化用于将抗癌药物可控和持续递送到肿瘤微环境（TME）中。在这里，我们回顾了用于癌症治疗的工程细菌的最新进展，以及增强治疗有效载荷传递的其他工程策略。我们还探讨了组合疗法的使用，包括工程细菌和传统抗癌疗法，以解决肿瘤内异质性问题。最后，我们讨论了用于癌症预防和治疗的工程细菌的开发和临床转化的前景。
